- Home
- BBIO vs OBDC Comparison
BBIO vs OBDC Comparison
Compare BBIO & OBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- OBDC
- Stock Information
- Founded
- BBIO 2015
- OBDC 2015
- Country
- BBIO United States
- OBDC United States
- Employees
- BBIO N/A
- OBDC N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- OBDC Investment Managers
- Sector
- BBIO Health Care
- OBDC Finance
- Exchange
- BBIO Nasdaq
- OBDC Nasdaq
- Market Cap
- BBIO 5.6B
- OBDC 6.0B
- IPO Year
- BBIO 2019
- OBDC 2019
- Fundamental
- Price
- BBIO $36.08
- OBDC $14.92
- Analyst Decision
- BBIO Strong Buy
- OBDC Hold
- Analyst Count
- BBIO 13
- OBDC 7
- Target Price
- BBIO $48.33
- OBDC $15.42
- AVG Volume (30 Days)
- BBIO 2.5M
- OBDC 2.4M
- Earning Date
- BBIO 02-20-2025
- OBDC 02-19-2025
- Dividend Yield
- BBIO N/A
- OBDC 9.94%
- EPS Growth
- BBIO N/A
- OBDC N/A
- EPS
- BBIO N/A
- OBDC 1.61
- Revenue
- BBIO $217,765,000.00
- OBDC $1,613,593,000.00
- Revenue This Year
- BBIO $2,309.33
- OBDC $2.78
- Revenue Next Year
- BBIO N/A
- OBDC $11.69
- P/E Ratio
- BBIO N/A
- OBDC $9.23
- Revenue Growth
- BBIO 2209.77
- OBDC 6.06
- 52 Week Low
- BBIO $21.62
- OBDC $13.98
- 52 Week High
- BBIO $41.04
- OBDC $16.91
- Technical
- Relative Strength Index (RSI)
- BBIO 73.73
- OBDC 46.01
- Support Level
- BBIO $33.73
- OBDC $14.48
- Resistance Level
- BBIO $36.24
- OBDC $15.21
- Average True Range (ATR)
- BBIO 1.63
- OBDC 0.22
- MACD
- BBIO 0.65
- OBDC -0.02
- Stochastic Oscillator
- BBIO 97.63
- OBDC 38.94
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About OBDC Blue Owl Capital Corporation
Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.